Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.64 |
| ▸ | GSK3B | P49841 | 7/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.56 |
| ▸ | CLK1 | P49759 | 4/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.54 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.53 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.48 |
| ▸ | CDK9 | P50750 | 4/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491392 | 0.86 | DYRK1A (0.75) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL19100699 | 0.83 | CDK5 (0.71) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL30957480 | 0.83 | DYRK1A (0.56) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL17542614 | 0.83 | AR (0.62) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL30957630 | 0.83 | AR (0.62) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL4487796 | 0.83 | DYRK1A (0.56) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL24900746 | 0.80 | DYRK1A (0.73) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL30436509 | 0.80 | DYRK1A (0.73) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL19100649 | 0.80 | DYRK1A (0.53) | DYRK1AGSK3BCDK5CDK5R1CLK1 | |
| SCHEMBL21870744 | 0.80 | DYRK1A (0.51) | DYRK1AGSK3BCDK5CDK5R1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319670-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| CN-111848586-B | Compounds and methods for inhibiting JAK | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-4219482-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219482-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-10167276-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| CN-108368091-A | COMPOUNDS AND METHODS FOR INHIBITING JAK | 迪哲（江苏）医药有限公司 | 2018-08-03 | — | — | CN | disclosed |
| EP-3353168-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | Dizal (Jiangsu) Pharmaceutical Co., Limited (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | US | disclosed |
| WO-2017050938-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017050938-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | DYRK1A 3057/4885GSK3B 796/4885CDK5 347/4885 |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | DYRK1A 3057/4885GSK3B 796/4885CDK5 347/4885 |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | DYRK1A 3057/4885GSK3B 796/4885CDK5 347/4885 |
| US-10167276-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | DYRK1A 3057/4885GSK3B 796/4885CDK5 347/4885 |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | DYRK1A 3057/4885GSK3B 796/4885CDK5 347/4885 |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | DYRK1A 3057/4885GSK3B 796/4885CDK5 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.